Smoking is one of the most important lifestyle factors causing death and disability. It is the main contributor to cancer and heart diseases as well as respiratory diseases which account for almost 70% of all deaths across the globe. Control on tobacco is recognized as a worldwide problem as tobacco manufacturers focus mainly on targeting the developing regions. Nicotine addiction is the second leading cause of deaths worldwide. According to the Centers for Disease Control and Prevention (CDC), around 44 million adults got addicted to cigarette smoking in 2011, with majority being from the low-income class in the U.S. Similar conditions prevail in other countries and pose an equal threat to human lives.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/906
The products used in smoking cessation therapy include nicotine replacement therapy (NRT) products as well as prescription drugs consisting of antidepressants and nicotine receptor agonists. The NRT market segment comprises nicotine gums, transdermal patches, lozenges, nasal and oral sprays, inhalers and sublingual tablets. NRT products, except Nicotrol nasal sprays and inhaler by Pfizer, are over-the-counter (OTC) products and are easily available in convenience stores and can be ordered online. This has provided tremendous leverage for market growth. Generic and branded generic forms of bupropion are expected to pose a challenge to the branded drugs scheduled to face patent expiry in the near future. Electronic cigarettes (e-cigarette) have changed the entire course of the market with a double digit growth rate. Although e-cigarettes have been banned in some countries, the market is expected to grow at a fast rate. It has been observed that nicotine gums and lozenges are used by addicts who wish to reduce smoking. This population of reducers is different from quitters who aim to completely quit smoking. Tobacco addicts cannot simultaneously smoke while using a patch, which can be harmful to the body. Generic forms of drugs have saturated the market with variants of Zyban. Some drug developers have even initiated clinical trials for nicotine vaccines. Although developments are taking place in the drug therapy market, the NRT market also holds immense potential because of the low cost, over-the-counter and online sales.
Inquiry on this report @ http://www.mrrse.com/enquiry/906
The global smoking cessation and nicotine de-addiction products market was dominated by North America in terms of revenue in 2014, followed by Europe. The Asia Pacific region is expected to display high growth rate during the forecast period 2015 to 2023. This market is sustained by the large number of people wanting to quit smoking. Furthermore, the smoking cessation market in emerging economies of the Middle East, Latin America and Africa will add to the growth of this market. The high cost associated with smoking cessation products relative to the cost of continued smoking may discourage the use of these products and drugs, thus adversely impacting the quitting rates. According to the WHO, Australia tops the list of regions with high cigarette prices after Norway. Research on the impact of cost on accessing cessation services will consequently affect the growth of the smoking cessation products market. Developing countries are thus currently focusing on implementing various vital public health strategies which include discouragement of smoking initiation and reducing the use of tobacco. Physicians may play a key role in promoting smoking cessation because of their close contact with the public. This practice can be efficacious and cost-effective with regards to patient smoking outcome. Also, raising taxes to increase the cost of cigarettes can reduce tobacco use, cut smoking rates, and ultimately save lives.
Read Complete Report with TOC @ http://www.mrrse.com/smoking-cessation-nicotine-de-addiction-products
Smoking prevalence has been varying across the globe with many developing countries witnessing rapid increase in the prevalence rate, which will create huge health problems for the future if left unchecked. The key players dominating the global smoking cessation products market comprises GSK, Pfizer, and NJOY.
90 State Street,
Albany NY – 12207